Correlation Engine 2.0
Clear Search sequence regions

  • alleles (2)
  • control group (1)
  • FSH (1)
  • fsh receptor (1)
  • fsh β subunit (4)
  • FSHR (1)
  • gene (5)
  • gonadotropins (1)
  • helps (1)
  • women (3)
  • Sizes of these terms reflect their relevance to your search.

    Molecular biology tools, such as the detection of single nucleotide polymorphisms (SNPs), have been considered to assist to the management of the ovarian stimulation protocols. The aim of this study was to evaluate the impact of two polymorphisms, the Asn680Ser polymorphism of the FSHR gene, and the FSH β subunit (FSHβ) gene polymorphism -211 G>T, in a Greek population of women undergoing IVF/ICSI program in our center. In addition, a control group of fertile women was studied, to verify whether there are differences in the genotype distribution between fertile and infertile population for both polymorphisms, as the FSHβ gene polymorphism -211 G>T is studied for the first time in the Greek population. The FSH β-211 G>T polymorphism, studied for the first time in the Greek infertile population, appears to be quite rare. When studying the two polymorphisms separately, statistically significant differences were obtained that concerned the LH levels. According to the combination analysis of the two polymorphisms by the number of alleles, women with 2-3 polymorphic alleles needed more days of stimulation, but there were no differences in pregnancy rates. This molecular genetic study helps to elucidate whether the polygenic combination of the Asn680Ser and FSH β subunit -211 G>T gene polymorphisms is of additive value in the prediction of ovarian response to exogenous gonadotropins. Copyright© Bentham Science Publishers; For any queries, please email at


    Elli Anagnostou, Alexia Kafkoutsou, Despina Mavrogianni, Ekaterini Domali, Evangelia Dimitroulia, Dimitris Mathiopoulos, Peter Drakakis, Dimitris Loutradis. Individual and Combined Assessment of Ser680Asn FSH Receptor and FSHβ -211 G>T Gene Polymorphisms in Ovarian Response in IVF/ICSI Program. Current pharmaceutical biotechnology. 2020 Oct 29

    PMID: 33121406

    View Full Text